Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer

被引：16
|
作者：
Moore-Smith, Lakisha [1 ]
Forero-Torres, Andres [2 ]
Stringer-Reasor, Erica [3 ]
机构：
[1] Brookwood Baptist Hlth Princeton, Dept Med, 833 Princeton Ave,POB 3 Suite 200, Birmingham, AL 35211 USA
[2] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, 1720 2nd Ave South,NP 2517, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, 1720 2nd Ave South,NP 2501, Birmingham, AL 35294 USA
来源：
SURGICAL CLINICS OF NORTH AMERICA | 2018年 / 98卷 / 04期
关键词：
Neoadjuvant chemotherapy; Early stage breast cancer; Triple-negative breast cancer; Targeted therapy; COMPLETE RESPONSE RATES; PHASE-II; AND/OR BEVACIZUMAB; WEEKLY PACLITAXEL; PEMBROLIZUMAB; CHEMOTHERAPY; CARBOPLATIN; SUNITINIB; SUBTYPES; IMPACT;
D O I：
10.1016/j.suc.2018.04.004
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Breast cancer is the second leading cause of cancer-related death in women in the United States. In general, advances in targeted treatment for breast cancer have improved over the last 20 years, except in the triple-negative breast cancer (TNBC) subtype. TNBC is an aggressive breast cancer subtype with limited treatment options as compared with hormone-positive breast cancers. Genomic profiling of TNBC has shown promise in aiding clinicians to develop personalized targeted agents. Prioritizing novel molecular-based therapies in the neoadjuvant setting may help investigators understand mechanisms of resistance and ultimately improve patient outcomes in TNBC.
引用
收藏
页码：773 / +
页数：14
相关论文
共 50 条
  • [1] The prognosis of effectiveness neoadjuvant therapy in patients with triple-negative breast cancer
    Vyzhigina, B.
    [J]. BREAST, 2019, 44 : S67 - S67
  • [2] Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
    Yam, Clinton
    Yen, Er-Yen
    Chang, Jeffrey T.
    Bassett, Roland L., Jr.
    Alatrash, Gheath
    Garber, Haven
    Huo, Lei
    Yang, Fei
    Philips, Anne, V
    Ding, Qing-Qing
    Lim, Bora
    Ueno, Naoto T.
    Kannan, Kasthuri
    Sun, Xiangjie
    Sun, Baohua
    Cuentas, Edwin Roger Parra
    Symmans, William Fraser
    White, Jason B.
    Ravenberg, Elizabeth
    Seth, Sahil
    Guerriero, Jennifer L.
    Rauch, Gaiane M.
    Damodaran, Senthil
    Litton, Jennifer K.
    Wargo, Jennifer A.
    Hortobagyi, Gabriel N.
    Futreal, Andrew
    Wistuba, Ignacio I.
    Sun, Ryan
    Moulder, Stacy L.
    Mittendorf, Elizabeth A.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5365 - 5375
  • [3] Efficacy of neoadjuvant systemic carboplatin therapy in triple-negative breast cancer
    Thomssen, Christoph
    Schuler, Kathleen
    Bauer, Marcus
    Reinhardt, Kristin
    Strauss, Hans-Gerorg
    Vetter, Martina
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [4] Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
    Silva, Diogo
    Mesquita, Alexandra
    [J]. BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2022, 16
  • [5] Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
    Bezerra de Mello, Ramon Andrade
    Perez, Katia Roque
    Vazquez, Thais Perez
    [J]. IMMUNOTHERAPY, 2024, 16 (04) : 257 - 266
  • [6] Neoadjuvant treatments for triple-negative breast cancer (TNBC)
    von Minckwitz, G.
    Martin, M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 35 - 39
  • [7] Neoadjuvant platin and bevacizumab in triple-negative breast cancer
    Kern, P.
    Otterbach, F.
    Kolberg, H. C.
    Pott, D.
    Kalisch, A.
    Kimmig, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
    Silver, Daniel P.
    Richardson, Andrea L.
    Eklund, Aron C.
    Wang, Zhigang C.
    Szallasi, Zoltan
    Li, Qiyuan
    Juul, Nicolai
    Leong, Chee-Onn
    Calogrias, Diana
    Buraimoh, Ayodele
    Fatima, Aquila
    Gelman, Rebecca S.
    Ryan, Paula D.
    Tung, Nadine M.
    De Nicolo, Arcangela
    Ganesan, Shridar
    Miron, Alexander
    Colin, Christian
    Sgroi, Dennis C.
    Ellisen, Leif W.
    Winer, Eric P.
    Garber, Judy E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1145 - 1153
  • [9] How high a bar to change neoadjuvant therapy for triple-negative breast cancer?
    Kuritzky, Benjamin
    Sikov, William M.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (04) : 293 - 296
  • [10] Biomarkers for Personalized Neoadjuvant Therapy in Triple-Negative Breast Cancer: Moving Forward
    Rauch, Gaiane M.
    [J]. RADIOLOGY, 2024, 312 (03)
12345